Isoform selective PI3 kinase inhibitors for cancer, thrombosis and inflammatory disease

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1093062

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Inhibitors of the PI3 kinase family of enzymes have potential as therapeutics in diseases such as cancer, thrombosis and inflammatory disease. In this project the investigators will develop a new class of PI3 kinase inhibitors they have discovered, optimizing their pharmaceutical properties and evaluating them in models of disease. The aim is to develop a candidate for human clinical studies.

Funded Activity Details

Start Date: 01-01-2015

End Date: 01-01-2016

Funding Scheme: Development Grants

Funding Amount: $474,473.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Biologically Active Molecules

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

anticancer drug | drug discovery | inflammatory diseases | kinase inhibitors | platelet aggregation

Related Links